Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
This article was originally published in The Pink Sheet Daily
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
You may also be interested in...
AMT halves head count and restructures following second rejection by European regulators of its potential gene therapy, Glybera.
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
Belgian start-up raises record-breaking €18 million A round to take rho kinase inhibitor glaucoma candidate to clinical proof-of-concept.